When Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies, several of its competitors saw their stocks rise – including Biogen and Eisai.

Roche announced its investigational antibody gantenerumab failed to meet the primary endpoints in GRADUATE I and II – two Phase III studies in Alzheimer’s disease.

A Roche executive said on Tuesday that positive trial data on an Alzheimer’s disease drug candidate by rival Biogen was encouraging for companies such as Roche also pursuing amyloid beta proteins as a drug target.

Today’s promising results from Eisai and Biogen’s Alzheimer’s drug trial have reignited decades-old hopes that targeting a particular protein helps arrest the progression of the fatal brain disease, giving a big boost to similar studies being run by Roche and Eli Lilly.